Life Science Investing Aclaris Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update
Life Science Investing Aclaris Therapeutics to Host In-Person and Webcast R&D Day, "Patient Focused Innovation: Addressing Gaps in Immuno-Inflammatory Markets", in New York on October 14, 2025
Life Science Investing Aclaris Therapeutics Announces Late-Breaking Abstract and Oral Presentation On ATI-2138 Phase 2a Results at the 2025 European Academy of Dermatology and Venereology Congress
Locksley Enters into Sponsored Research Agreement with Columbia University to Develop Advanced Sustainable Processing Technologies for Rare Earth Elements and Critical Metal Recovery
Noble Minerals Acquires a Rare Earth Property in the vicinity of the Montviel Rare Earth Resource, Quebec, Canada
